BIRC5 and hepatocellular carcinoma: Sorafenib, the first-line chemotherapy agent for advanced HCC, sensitizes resistant HCC cells to radiation-induced apoptosis by inhibiting STAT3 phosphorylation and reducing BIRC5 expression84.